Skip to main content

ADVERTISEMENT

CLL/MCL

dr phillips
Videos
07/08/2021
Tycel Phillips, MD, discusses the use of venetoclax, lenalidomode, and rituximab in patients with newly diagnosed MCL. These data were presented at the 2021 ASCO Annual Meeting.
Tycel Phillips, MD, discusses the use of venetoclax, lenalidomode, and rituximab in patients with newly diagnosed MCL. These data were presented at the 2021 ASCO Annual Meeting.
Tycel Phillips, MD, discusses...
07/08/2021
Oncology
Dr Riedell
Videos
07/02/2021
Peter Riedell, MD, discusses the impact of time to relapse on OS in patients with MCL following front-line high-dose therapy and autoHTC.
Peter Riedell, MD, discusses the impact of time to relapse on OS in patients with MCL following front-line high-dose therapy and autoHTC.
Peter Riedell, MD, discusses the...
07/02/2021
Oncology
dr martin
Podcasts
06/07/2021
Peter Martin, MD, discusses various treatment patterns and outcomes of patients with MCL over the past 10 years; these data were presented at the 2021 ASCO Annual Meeting.
Peter Martin, MD, discusses various treatment patterns and outcomes of patients with MCL over the past 10 years; these data were presented at the 2021 ASCO Annual Meeting.
Peter Martin, MD, discusses...
06/07/2021
Oncology
Conference Insider
03/19/2021
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Patients with NHL with...
03/19/2021
Oncology
Conference Insider
03/19/2021
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN 2021 Virtual Annual Conference.
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN 2021 Virtual Annual Conference.
Study findings have led experts...
03/19/2021
Oncology
Conference Insider
03/18/2021
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
The current protocol for...
03/18/2021
Oncology
Conference Insider
03/18/2021
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
Study findings lead experts to...
03/18/2021
Oncology